Michele Stone, PhD
Vice President, Translational Development
Michele Stone is the Vice President of Translational Development at Kriya Therapeutics. Dr. Stone joins Kriya from Axovant Gene Therapies, where she was Vice President of Early Development and Head of Nonclinical and Bioanalytical. Prior to Axovant Gene Therapies, Dr. Stone was Executive Director of Vaccine Development and Bioanalytical at Liquidia Technologies. Dr. Stone was also the Director of R&D at Aeras where she was responsible for developing and leading partnerships to advance multiple vaccine platforms (viral vector, protein, and nucleic acid) into and through clinical development. In addition, Dr. Stone was a Senior Scientist at Canon US Life Sciences where she contributed to the development of diagnostics targeted towards personalized medicine.
Dr. Stone received her PhD in biochemistry and molecular biology and completed her postdoctoral fellowship in physiology and neuroscience at the University of Maryland, Baltimore. Dr. Stone received her undergraduate degree in chemistry at Lynchburg College.